Oxford BioDynamics PLC PDMR Dealing (6120K)
30 August 2019 - 12:30AM
UK Regulatory
TIDMOBD
RNS Number : 6120K
Oxford BioDynamics PLC
29 August 2019
29 August 2019
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
PDMR Dealing
Oxford BioDynamics Plc (AIM: OBD) announces that it has today
received notice that Vulpes Life Sciences Fund, which is controlled
by Non-Executive Director, Stephen Diggle, has purchased 4,500
Ordinary Shares of 1 pence each at a price of 90p per share.
Following this transaction, Vulpes Life Sciences Fund is
interested in 11,734,725 Ordinary Shares, representing
approximately 12.68% of the Company's current issued share
capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details:
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Stephen Diggle
------------------------------- --------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------
a) Position/status Director/PDMR
------------------------------- --------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------------- --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Oxford BioDynamics Plc
------------------------------- --------------------------------------
b) LEI 2138005Y1TK258O5U928
------------------------------- --------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the Ordinary Shares of 1 pence each
financial instrument, ISIN: GB00BD5H8572
type of instrument
Identification code
------------------------------- --------------------------------------
b) Nature of the transaction Acquisition of ordinary shares
------------------------------- --------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.90 4,500
----------
------------------------------- --------------------------------------
d) Aggregated information Price Volume
- Aggregated volume 0.90 4,500
- Price -------
------------------------------- --------------------------------------
e) Dates of the transactions 28 August 2019
------------------------------- --------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- --------------------------------------
For further details please contact:
Oxford BioDynamics Plc
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO +44 (0)1865 518910
Shore Capital
Nominated Adviser and Broker
Stephane Auton
Edward Mansfield +44 (0)20 7408 4090
FTI Consulting
Financial Public Relations
Adviser
Brett Pollard
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for
Enterprise: Innovation. The Queen's Awards for Enterprise are the
most prestigious awards for UK businesses.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHPLMITMBTTBPL
(END) Dow Jones Newswires
August 29, 2019 10:30 ET (14:30 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024